Objective: Reportedly, melatonin protects the pancreatic islets and decreases insulin resistance; thus, it may contribute to preventing diabetes. Epidemiological data suggested that lower melatonin secretion is associated with higher incidence of diabetes in female nurses. Such associations are unknown in the general population. We evaluated the association between melatonin secretion and diabetes in a general population, including both genders.
| UME measurements
Participants were instructed to collect their urine overnight at home following the instructions in the urine collection protocol.
Participants had to dispose of the last void at bedtime and collect each subsequent void, including the first morning void. Samples were stored in a dark bottle with a cold pack at room temperature until the next day; the total volume was measured and stored at −20°C until analysis. Urinary 6-sulfatoxymelatonin levels were measured at a commercial laboratory (SRL, Inc., Tokyo, Japan) using an enzyme-linked immunosorbent assay kit (RE54031; IBL International, Hamburg, Germany) with high sensitivity. UME was calculated using the following formula: UME (μg) = 6-sulfatoxymelatonin level (μg/mL) × total overnight urine volume (mL). In cases wherein urine was not collected as per protocol, UME data were considered missing. UME reproducibility was evaluated by requesting the first 188 participants to provide an additional urine sample approximately 4 months following the date at which the first void sample was collected. The intraclass correlation coefficient between the two UME levels was previously reported to be 0.66 (95% confidence interval [CI] , 0.57-0.73). 16 
| Ascertainment of diabetes mellitus
Participants were instructed to fast overnight. On the following day, venous blood samples were obtained by two trained physicians approximately between 10:00 and 11:00 am. The samples were analysed to determine the concentrations of glycated haemoglobin (HbA1c) at a commercial laboratory (SRL Co., Inc.) using a standard clinical chemistry analyser. Participants were considered to have diabetes mellitus according to their medical history, current diabetes treatment, or HbA1c level ≥6.5% of the National Glycohemoglobin Standardization Program value.
| Measurements of other variables
Information on current smoking, drinking, and economic statuses and information on medication use were surveyed using a questionnaire. The caloric intake was assessed by a validated food frequency questionnaire, containing 29 food groups and 10 kinds of cookery.
The weekly intake of each food group was estimated by commonly used units or portion sizes. 17 Daytime physical activity was calculated as the average number of physical activity counts from getting out of bed in the morning to bedtime in the evening and was measured at 1-min intervals for 2 days using an actigraph (Actiwatch . For females, the result was multiplied by a correction factor of 0.739. Chronic kidney disease (CKD) was determined as <60 mL/min/1.73 m 2 . Body mass index (BMI) was calculated using body weight and height. Bedroom light intensity was measured at 1-min intervals using a portable light meter (LX-28SD; Sato Shouji Inc., Kanagawa, Japan) set in the bedroom, and the average light intensity during the in-bed period was used as a bedroom light intensity parameter. 
| Statistical analysis

| RE SULTS
The mean (SD) age of the 1096 participants was 71.8 (7.1) years, and 519 (47.4%) individuals were male. Diabetes prevalence was 17.5% in males and 10.7% in females (Table 1 ). In males with and without diabetes mellitus, the mean fasting plasma glucose was 7.7 and 5.4 mmol/L and HbA1c was 7.0% and 5.6% respectively. In females with and without diabetes mellitus, the mean fasting plasma glucose was 6.9 and 5.2 mmol/L and HbA1c was 6.9% and 5.6% respectively. Among males, diabetes mellitus was significantly associated with higher BMI (P = 0.048), and marginally associated with current smoking (P = 0.14), lower physical activity (P = 0.14), earlier bedtime (P = 0.14), and longer duration in bed (P = 0.07). Among females, diabetes mellitus was significantly associated with higher BMI (P < 0.001), and marginally associated with current smoking (P = 0.06) and lower physical activity (P = 0.08) and longer duration in bed (P = 0.17). Fifty-two males and 19 females were exposed to previous night shift work. Gender-specific analyses in the groups with and without diabetes suggested that male gender was significantly associated with current smoking, higher alcohol consumption, higher caloric intake, lower physical activity, and earlier bedtime in both groups with and without diabetes (Supporting Information   Table S1 ). Also, gender-specific associations between UME and variables were shown (Supporting Information Table S2 ).
The median UME of 1096 individuals was 6.7 μg (interquartile range, 4.0-10.5). Among males, the median UME was 3.2 (range, <4.8), 6.3 (4.8-8.0), 9.5 (8.0-11.6), and 15.6 (>11.6) μg in the lowest quartile group (Q1, n = 130), Q2 (n = 129), Q3 (n = 130), and the highest quartile group (Q4, n = 130) respectively. Among females, the median UME was 2.6 (range, <3.5), 4.6 (3.5-5.7), 7.1 (5.7-9.2), and 12.3 (>9.2) μg in Q1 (n = 144), Q2 (n = 145), Q3 (n = 144), and Q4
(n = 144) groups respectively. Overall, the mean (SD) UME was 2.0 (0.7) log μg in males and 1.7 (0.7) log μg in females. Diabetes prevalence decreased with increasing UME quartiles among males (Q1, Figure 1A ) but not among females (Q1, 13.2%; 95% CI, 7.7-18.7; Q2, 9.0%, 95% CI, 4.3-13.6; Q3, 9.0%, 95% CI, 4.3-13.7; Q4, 11, 8%; 95% CI, 6.5-17.1; P for trend = 0.96, Figure 1B ).
Among males, the unadjusted OR for diabetes mellitus was significantly lower in Q4 than in Q1 (OR, 0.43; 95% CI, 0.22-0.83; P = 0.012, Table 2 ). This association between UME and diabetes mellitus was consistent in the model using tertile data on UME (OR, 
| D ISCUSS I ON
Herein, we found that higher melatonin secretion was independently and significantly associated with lower diabetes prevalence in males but not in females. These gender differences observed in our cohort were robust and remained significant even after adjusting for potential confounding factors. Our data indicated that diabetes prevalence was approximately one-third in the highest melatonin quartile group compared with that in the lowest quartile group among males.
Our results add some novel findings to the current epidemiological evidence suggesting an association between melatonin secretion and diabetes mellitus. A nested case-control study of the Nurses'
Health Study cohort revealed that lower melatonin secretion based on a first morning void urine sample was independently associated with the diabetes incidence in the female population including 370 females with diabetes and 370 matched controls. 13 Although that study was the first report of prospective evidence suggesting an association between lower melatonin secretion and diabetes incidence, the generalizability of their results was limited given that the sample comprised only females and some participants may have been exposed to a significant amount of shift work. In our study, only 19 females (3.3%) had been exposed to previous shift work; among females, melatonin secretion was not significantly associated with diabetes prevalence. This discrepancy in the results between the female cohort and the present study may be caused by racial differences. Conversely, among males, physiological increases in melatonin secretion in the lowest to highest quartile groups (median, from 3.2 to 15.6 μg) were associated with a 63% (95% CI, 26%-82%) decrease in diabetes prevalence. Considering the results using continuous melatonin data, a 1 SD increase in melatonin secretion corresponded to a 28% (95% CI, 11-40%) decrease in diabetes prevalence.
F I G U R E 1
Gender-specific associations of urinary 6-sulfatoxymelatonin excretion quartiles with the diabetes prevalence. Solid bars indicate the diabetes prevalence in males (A) and that in females (B) . P values are shown for the trends determined by logistic regression analysis. CI, confidence interval
We performed a previous cross-sectional study wherein a lower melatonin secretion was independently associated with higher diabetes prevalence in a general elderly population of 513 individuals (male, n = 238). 16 However, in that study, we were unable to conduct gender-specific analyses because of the relatively small sample size.
Melatonin could play a role in preventing diabetes mellitus possibly through multiple pathways involved in the protection of β-cell function and decrease in insulin resistance. Oxidative stress induces reactive oxygen species and pancreatic islet damage, possibly leading to β-cell dysfunction. 18 Melatonin is a well-known antioxidant and free radical scavenger. 1, 5 Experimental studies in humans suggested that melatonin administration reduced systemic oxidative stress and pro-inflammatory cytokines, such as tumour necrosis factor alpha, which also play a crucial role in systemic insulin resistance. 7, 19 Pinealectomy increases nocturnal plasma insulin levels, and this effect is reversed by melatonin administration. 3, 4 Additionally, melatonin prevents insulin resistance in rat skeletal muscle. 20 A cross-sectional study reported an inverse association between melatonin secretion and insulin resistance based on the first morning void urine sample and insulin levels in 1075 female nurses without diabetes mellitus.
21
Another potential mechanism underlying the protective effect of melatonin on diabetes onset includes aligned circadian biological rhythmicity and better sleep. Melatonin is involved in circadian biological rhythmicity and sleep, and its receptors are located in human pancreatic islets. 1, 2 Numerous studies suggested that night shift workers, significantly related with chronic circadian misalignment and decreased melatonin secretion, exhibited higher glucose and insulin levels, leading to a higher diabetes risk. [10] [11] [12] 22 A human physiological study showed that circadian misalignment induced by a forced TA B L E 2 Gender differences in the OR for diabetes in relation to UME levels Quartiles of UME Continuous UME (log μg) BMI, body mass index; CI, confidence interval; OR, odds ratio; UME, urinary 6-sulfatoxymelatonin excretion. Model 1: Adjusted for age plus basic parameters (smoking and drinking status, BMI, household income, caloric intake, and physical activity). Model 2: Adjusted for age plus clinical parameters (β-blocker, benzodiazepine chronic kidney disease, bedtime, and duration in bed). Model 3: Adjusted for age plus basic and clinical parameters (smoking and drinking status. BMI, household income, caloric intake, physical activity, β-blocker, benzodiazepine chronic kidney disease, bedtime, and duration in bed).
desynchrony protocol increased glucose levels despite increased insulin levels. 9 Additionally, partial sleep deprivation even for one night induces insulin resistance in healthy humans. 23 Recent studies suggested that melatonin regulates energy expenditure through growing and activating brown adipose tissue. 8 Nevertheless, herein, the significant association between melatonin secretion and diabetes mellitus in males was independent of sleep parameters and BMI.
We observed gender differences in the association between melatonin secretion and diabetes prevalence, although the underlying mechanisms are largely unknown. Previous studies reporting associations of melatonin secretion with diabetes incidence and insulin resistance included only female nurses with a median age of 64 years (range, 56-75 years) and 43 years (range, 36-49 years) respectively. 13, 21 Thus, those female populations were younger than our female population (median age of 72 years [range, 60-91 years]).
We previously reported that elderly females have significantly lower melatonin secretion than elderly males. 24 However, in a younger population, several studies suggested that females have a higher melatonin secretion than males. 25, 26 In addition, diabetes prevalence was lower in females than in males; therefore, case size was significantly smaller in females than males (n = 62 vs 91 respectively). These age differences and a smaller sample of females with diabetes mellitus, in addition to variable exposure to shift work, may explain, at least partly, the differences between the present results and those of the previous nurses' study. To the best of our knowledge, this is the first report of an association between melatonin secretion and diabetes mellitus in a male population. Our study is the first large-scale study of this nature to include data of both genders. However, further prospective studies are needed to better understand the association between melatonin secretion and diabetes mellitus.
The present study has several potential limitations. First, because of the cross-sectional study design, we could not establish a causal relationship between the variables studied. Second, UME was only measured for one night; however, the reproducibility for the UME levels was moderate. Third, although our statistical models were adjusted for night-time light exposure and other major potentially confounding factors, the possible confounding effects by factors we did not measure cannot be excluded, especially in elderly populations. Thus, further researches investigating the association between melatonin levels and diabetes in a younger population including both genders are needed.
In conclusion, in the present cohort, higher melatonin secretion was significantly associated with lower diabetes prevalence in males but not in females. Our results remained significant even after adjusting for potential confounding factors. Prospective studies further investigating the association between melatonin secretion and diabetes mellitus in males and females are needed.
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